Loading
institutionsInstitution
Institut de Cancérologie de Lorraine
The Institut de Cancérologie de Lorraine, formerly the Centre Alexis Vautrin, is the Unicancer comprehensive cancer centre for Lorraine near Nancy and a full member of the Organisation of European Cancer Institutes.
Also called: ICLCentre Alexis Vautrin
Overview
The Institut de Cancérologie de Lorraine (ICL), previously known as the Centre Alexis Vautrin, is the comprehensive cancer centre for the Lorraine region, located at Vandœuvre-lès-Nancy on the Brabois hospital campus near Nancy, with origins going back to 1924. It is one of the centres de lutte contre le cancer in the Unicancer network and works with the University of Lorraine and the Nancy university hospital. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here.
Location
Vandœuvre-lès-Nancy, FR
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#594 · 4 points (0 Newsweek + 0 NCI + 4 from 2 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Institut de Cancérologie de Lorraine, including child institutions. 175 works · 2,594 citations · 66% open access · 19% clinical trials · 1% reviews.
Oncology works per year
332022
382023
412024
372025
262026
Most works
- Aurélien Lambert41 works
- Thierry Conroy38 works
- Alexandre Harlé19 works
- Jean‐Sébastien Frenel12 works
- Jérôme Cros11 works
- Olivier Bouché11 works
- Peter Ellmark10 works
- Ivan Borbath10 works
- Karen Geboes10 works
- Antonio Di Meglio10 works
Most cited
Didier Peiffert
Representative of Institut de Cancérologie de Lorraine to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Didier Peiffert represents Institut de Cancérologie de Lorraine in the Organisation of European Cancer Institutes, which lists the centre among its members in France.
Thierry Conroy
Medical Oncologist, Institut de Cancérologie de Lorraine; Professor, University of Lorraine
Pancreatic cancerChemotherapy regimensAdjuvant therapy
Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings.
Similar pages
- InstitutionInstitut Godinot
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionInstitut Strauss
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionInstitut du Cancer de Montpellier (ICM)
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionCentre François Baclesse
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionCentre Jean Perrin
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionCentre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes.
- InstitutionCentre Eugène Marquis
Shares UNICANCER, Organisation of European Cancer Institutes.
- TrialPRODIGE 4 / ACCORD 11
Shares Thierry Conroy, UNICANCER.